Your browser doesn't support javascript.
loading
Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases.
Li, Jianglei; Yu, Meihong; Fu, Shifeng; Liu, Deliang; Tan, Yuyong.
Afiliação
  • Li J; Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
  • Yu M; Research Center of Digestive Disease, Central South University, Changsha, China.
  • Fu S; Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
  • Liu D; Research Center of Digestive Disease, Central South University, Changsha, China.
  • Tan Y; Department of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, China.
Front Pharmacol ; 13: 907981, 2022.
Article em En | MEDLINE | ID: mdl-35652048
ABSTRACT
The deacetylation process regulated by histone deacetylases (HDACs) plays an important role in human health and diseases. HDAC6 belongs to the Class IIb of HDACs family, which mainly modifies non-histone proteins located in the cytoplasm. HDAC6 plays a key role in tumors, neurological diseases, and inflammatory diseases. Therefore, targeting HDAC6 has become a promising treatment strategy in recent years. ACY-1215 is the first orally available highly selective HDAC6 inhibitor, and its efficacy and therapeutic effects are being continuously verified. This review summarizes the research progress of ACY-1215 in cancer and other human diseases, as well as the underlying mechanism, in order to guide the future clinical trials of ACY-1215 and more in-depth mechanism researches.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article